FAMEGLOW(08603) plans to transfer to listing on the main board.

FAMEGLOW (08603) announced that the company has submitted an application for transfer listing to the Stock Exchange on December 8, 2025, in accordance with Chapter 9B of the Main Board Listing Rules. The transfer listing will not involve the issuance of any new shares by the company. The board of directors believes that transferring from GEM to the Main Board will significantly enhance the company's corporate image and public recognition, given the Main Board's larger market capitalization, higher trading volume, and relatively higher international visibility. As a mature medical beauty service provider in Hong Kong, the group believes that the stricter listing requirements of the Main Board and its representation of quality status are a strong recognition of its operational performance and market position. The anticipated enhancement of reputation is expected to strengthen the company's ability to attract and retain high-quality customers, business partners, and talent, as well as to better seize new business opportunities. Furthermore, the board of directors believes that the Main Board listing will expand the company's channels to a wider range of investors, including institutional investors, professional investors, and international participants, thereby broadening and diversifying the shareholder base. The transfer listing is also expected to enhance the company's financing flexibility, enabling it to access a more diverse range of debt financing options on more favorable terms. This move will support the optimization of the capital structure and provide more strategic financial management space. The board of directors believes that the transfer listing will have a positive impact on the group's sustainable growth and long-term development, thereby consolidating its leading position in the field of medical beauty and creating lasting value for the company and its shareholders. The board of directors believes that the transfer listing will have a positive impact on the group's sustainable growth and long-term development, thereby consolidating its leading position in the field of medical beauty and creating lasting value for the company and its shareholders.